伏立诺他临床应用新进展

发布时间：2018-06-06 15:44

本文选题：伏立诺他 + 皮肤T细胞淋巴瘤　；参考：《中国新药杂志》2015年08期

【摘要】：伏立诺他作为一种组蛋白去乙酰化酶抑制剂,已在2006年被美国FDA批准用于皮肤T细胞淋巴瘤(CTCL)的治疗,近年来随着研究的不断深入,伏立诺他在其他肿瘤治疗领域也有了较好的疗效,伏立诺他联合吉妥单抗及阿扎胞苷治疗老年复发性或难治性急性髓系细胞白血病(AML)有效率可达40%,联合地西他滨治疗复发性或难治性急性淋巴细胞白血病(AL)有效率为46.2%,联合硼替佐米治疗多发性骨髓瘤(MM)无疾病进展生存期为7.63个月,另外在晚期乳腺癌和骨髓移植患者免疫功能改善方面都有较好的作用。本文通过对伏立诺他近期国外的临床应用进行了文献检索,并将其应用新进展进行综述。
[Abstract]:As a histone deacetylase inhibitor, volenoate has been approved by the United States FDA in 2006 for the treatment of cutaneous T-cell lymphoma (CTCLs). He also has good results in other areas of cancer treatment. The effective rate of Volinota combined with gitumab and azacytidine in the treatment of recurrent or refractory acute myeloid leukemia (AML) in the elderly can reach 40%, and the effective rate of combination of dicitabine and desitabine in the treatment of recurrent or refractory acute lymphoblastic leukemia (ALL) is up to 40%. The progressive survival time of patients with multiple myeloma (MMM) treated with bortezomil was 7.63 months. In addition, it can improve immune function in patients with advanced breast cancer and bone marrow transplantation. In this paper, a literature review on the recent clinical application of Volinotaxel was carried out, and the new progress in its application was reviewed.
【作者单位】：国药一心制药有限公司;
【分类号】：R979.1

【共引文献】